WO2008149163A3 - Potassium ion channel modulators and uses thereof - Google Patents

Potassium ion channel modulators and uses thereof Download PDF

Info

Publication number
WO2008149163A3
WO2008149163A3 PCT/GB2008/050423 GB2008050423W WO2008149163A3 WO 2008149163 A3 WO2008149163 A3 WO 2008149163A3 GB 2008050423 W GB2008050423 W GB 2008050423W WO 2008149163 A3 WO2008149163 A3 WO 2008149163A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aralkyl
aryl
hydrogen
diseases
Prior art date
Application number
PCT/GB2008/050423
Other languages
French (fr)
Other versions
WO2008149163A2 (en
Inventor
Geoff Lawton
Original Assignee
Lectus Therapeutics Ltd
Geoff Lawton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lectus Therapeutics Ltd, Geoff Lawton filed Critical Lectus Therapeutics Ltd
Publication of WO2008149163A2 publication Critical patent/WO2008149163A2/en
Publication of WO2008149163A3 publication Critical patent/WO2008149163A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of general formula (1) and pharmacologically acceptable salts and pro-drugs thereof: wherein A and B are CH2 or CH2CH2, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, D, E and G are CR2 or nitrogen, with the proviso that at least one of D, E and G is nitrogen, R2, R3 and R4 are hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano, X is R5SO2, R5R7NCO, R5R7NSO2or R5SO2NR7CO, Y is R6CO, R6SO2, R6R7NCO, R6R7NSO2, R6SO2NR7CO or CO2R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, are of use inthe prophylaxis or treatment of diseases and conditions in which Kv1.x channels are involved, such as lower urinary tract disorders, cardiovascular diseases, inflammatory and immunological diseases and pain.
PCT/GB2008/050423 2007-06-06 2008-06-06 Potassium ion channel modulators and uses thereof WO2008149163A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0710844.2 2007-06-06
GBGB0710844.2A GB0710844D0 (en) 2007-06-06 2007-06-06 Potassium ion channel modulators & uses thereof

Publications (2)

Publication Number Publication Date
WO2008149163A2 WO2008149163A2 (en) 2008-12-11
WO2008149163A3 true WO2008149163A3 (en) 2009-04-09

Family

ID=38318820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050423 WO2008149163A2 (en) 2007-06-06 2008-06-06 Potassium ion channel modulators and uses thereof

Country Status (2)

Country Link
GB (1) GB0710844D0 (en)
WO (1) WO2008149163A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
GB0909672D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
JO3466B1 (en) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co Tetrahydropyridopyrazines modulators of gpr6
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
PT3207043T (en) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Dihydropyrrolopyridine inhibitors of ror-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2856931T3 (en) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc ROR-gamma modulators
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
AU2017208119B2 (en) 2016-01-15 2019-11-07 Pfizer Inc. 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN107021965B (en) * 2017-05-16 2019-08-13 无锡捷化医药科技有限公司 A method of synthesis -2 amine of 5,6,7,8- tetrahydro -1,6- naphthyridines
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
AR112461A1 (en) 2017-07-24 2019-10-30 Vitae Pharmaceuticals Inc PROCESSES FOR THE PRODUCTION OF SALTS AND CRYSTAL FORMS OF RORg INHIBITORS
KR20230142746A (en) * 2021-02-05 2023-10-11 시노허브 파마슈티컬 씨오., 엘티디 Plasmin inhibitor, method of preparation thereof and use thereof
WO2023231966A1 (en) * 2022-05-30 2023-12-07 赛诺哈勃药业（成都）有限公司 Use of tetrahydronaphthyridine derivative for preparing product for improving hyperpigmentation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0587180A2 (en) * 1992-09-11 1994-03-16 E.R. SQUIBB & SONS, INC. Aryl urea (Thiourea) and cyanoguanidine derivatives
EP0656350A1 (en) * 1993-10-07 1995-06-07 Bristol-Myers Squibb Company Biaryl urea and related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0587180A2 (en) * 1992-09-11 1994-03-16 E.R. SQUIBB & SONS, INC. Aryl urea (Thiourea) and cyanoguanidine derivatives
EP0656350A1 (en) * 1993-10-07 1995-06-07 Bristol-Myers Squibb Company Biaryl urea and related compounds

Also Published As

Publication number Publication date
WO2008149163A2 (en) 2008-12-11
GB0710844D0 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
WO2008149163A3 (en) Potassium ion channel modulators and uses thereof
WO2008038051A3 (en) Use of ion channel modulators in the prophylaxis and treatment of inflammatory and immunological diseases
MY153971A (en) Sulfonamides as trpm8 modulators
MX2009009492A (en) Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions.
WO2009051244A1 (en) Heterocyclic compound
WO2008126933A3 (en) Process for producing pesticidal benzamide compounds
WO2008116064A3 (en) Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
ATE383385T1 (en) 2-FLOUROALKYL-THIENO(3,4-B)THIOPHENE DERIVATIVES AND POLYMERS PRODUCED THEREFROM
WO2006071609A3 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2007087429A3 (en) Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007143422A3 (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
CY1111477T1 (en) SULFUR Pyridines as allosteric enhancers of the M4 muscarinic receptor
HK1137744A1 (en) N-pyridylpiperidine compound, method for producing the same, and pest control agent n-
HK1151288A1 (en) Acylthiourea compound or salt thereof, and use of the compound or the salt
WO2009146539A8 (en) 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
WO2006101867A3 (en) Treatment of inflammatory bowel disease
JO2634B1 (en) Compounds which have activity at M1 receptor and their uses in medicine
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
WO2007082262A3 (en) Novel compounds
WO2008136387A1 (en) Amide compound and use thereof
IN2012DN03846A (en)
WO2008136388A1 (en) Amide compound and use thereof for controlling plant diseases
WO2009014267A3 (en) Imidate compound and use thereof for pest control
WO2006029154A3 (en) Novel compounds
WO2008136389A1 (en) Amide compound and use thereof for controlling plant diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762533

Country of ref document: EP

Kind code of ref document: A2